Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-DLK-1/MMAE antibody-drug conjugate TORL-4-500

An antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against human delta-like 1 homolog protein (DLK-1; DLK1) conjugated, via a cleavable linker, to the cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-DLK-1/MMAE ADC TORL-4-500, the anti-DLK-1 antibody moiety targets and binds to DLK-1 expressed on tumor cells. Upon binding, internalization, and linker cleavage, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in DLK-1-expressing tumor cells. DLK-1, an epidermal growth factor (EGF)-like membrane bound protein overexpressed by certain tumor cell types and on certain cancer stem cells (CSCs), plays a key role in tumor cell proliferation. Its expression is widely expressed during fetal development but in adult healthy tissue it is very restricted.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC TORL-4-500
anti-DLK-1 ADC TORL-4-500
anti-DLK-1 antibody-drug conjugate TORL-4-500
anti-DLK-1/MMAE ADC TORL-4-500
antibody-drug conjugate TORL-4-500
Code name:TORL 4-500
TORL-4-500
TORL4-500
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search